Wednesday, October 14, 2026

CBOE Bullish Momentum With A 16% Rise In The Last 21 Sessions

ViaNews Editorial Team

October 27, 2023

CBOE Bullish Momentum With A 16% Rise In The Last 21 Sessions

(VIANEWS) - CBOE (VIX) has been up by 16.44% for the last 21 sessions. At 04:08 EST on Friday, 27 October, CBOE (VIX) is $20.19.

About CBOE's yearly highs and lows, it's 30.01% up from its 52-week low and 42.4% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was a negative 1.28%, a positive 0.66%, and a positive 5.08%, respectively.

CBOE's highest amplitude of average volatility was 5.71% (last week), 5.80% (last month), and 5.08% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CBOE's is considered to be oversold (<=20).

News about

  • According to MarketWatch on Wednesday, 25 October, "Despite the losing streak, the stock has gained 6.9% over the past three months through Tuesday, while the S&P 500 has lost 7.0%."
  • According to MarketWatch on Wednesday, 25 October, "The stock rose 2% premarket and is up 0.8% in the year to date, while the S&P 500 has gained 10.6%."
  • According to MarketWatch on Wednesday, 25 October, "The Dow Jones Industrial Average opened higher on Wednesday as a post-earnings rally in shares of Microsoft Corp. helped lift the blue-chip gauge while the S&P 500 and Nasdaq Composite sunk. ", "Meanwhile, the S&P 500 shed 22 points, or 0.5%, to 4,225, and the Nasdaq fell by 135 points, or 1.1%, to 13,000. "
  • According to DailyForex on Wednesday, 25 October, "However, it's important to acknowledge that the S&P 500 is currently characterized by a high degree of noise. ", "If the S&P 500 manages to breach this level, it's highly likely that the market will set its sights on the 50-day EMA as the next target."
  • According to MarketWatch on Wednesday, 25 October, "The stock has fallen 20.4% in the year to date, while the S&P 500 has gained 10.6%."

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com